POMT1 mutations can result in a disease spectrum of congenital muscular dystrophy, ranging from severe Walker-Warburg syndrome to milder phenotypes with brain abnormalities but lacking severe eye involvement.
Answers are grounded in this paper and cite their sources.
Expands POMT1-related congenital muscular dystrophy spectrum beyond Walker-Warburg syndrome; leaves open need for larger studies to guide testing and counseling.
The importance of O-glycosylation of alpha-dystroglycan (alpha-DG) is evident from the identification of POMT1 mutations in Walker-Warburg syndrome (WWS). Approximately one-fifth of the WWS patients show mutations in POMT1, which result in complete loss of protein mannosyltransferase activity. WWS patients are characterized by congenital muscular dystrophy (CMD) with severe brain and eye abnormalities. This suggests a crucial role for alpha-DG during development of these organs and tissues. Here we report new POMT1 mutations and polymorphisms in WWS patients. In addition, we report different compound heterozygous POMT1 mutations in four unrelated families that result in a less severe phenotype than WWS, characterized by CMD with calf hypertrophy, microcephaly, and mental retardation. Compared to WWS patients, these patients have milder structural brain abnormalities, and eye abnormalities were absent, except for myopia in some cases. In these patients we postulate that one or both transcripts for POMT1 confer residual protein O-mannosyltransferase activity. Our data suggest the existence of a disease spectrum of CMD including brain and eye abnormalities resulting from POMT1 mutations.
No takes yet. Share an insight, caveat, or question.
Reeuwijk et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: